NielsjeB schreef op 18 september 2015 17:53:
Published: 17:16 CEST 18-09-2015 /GlobeNewswire /Source: MDxHealth (R) / : MDXH /ISIN: BE0003844611
MDxHealth (R): Completion of the acquisition of NovioGendix - New share capital amount and new number of shares
IRVINE, CA, and HERSTAL, BELGIUM - September 18, 2015 - MDxHealth SA (Euronext Brussels: MDXH) (the "Company") announced today that it succesfully completed the acquisition of all of the shares in NovioGendix Holding B.V. ("NovioGendix"). The acquisition of NovioGendix was announced on September 15, 2015 and the completion of the acquisition took place on September 18, 2015.
As part of the consideration that was paid for the shares in NovioGendix, the Company issued 1,086,956 new shares at an issue price of EUR 4.14 representing the average closing price of the Company's shares on Euronext Brussels during a period of 30 days ending on September 17, 2015.
In conformity with article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, the Company announces that further to the issuance of the new shares, the Company's share capital was increased from € 35,097,093.09 to € 35,964,157.89, and its number of issued and outstanding shares was increased from 43,998,490 to 45,085,446 ordinary shares.
In addition to the outstanding shares, the total number of existing warrants (whether or not already granted or already vested) on the date of this press release amounts to 2,549,413 warrants which (if exercised) would entitle their holders to 2,678,565 shares with voting rights.
hugin.info/137314/R/1953245/710747.pdf